Ryota Otoshi

Dr. Ryota Otoshi


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

13 April 2024 in Respiratory Investigation
Verified
Journal Article
Closed access
TKTaichi Kaneko
Taichi Kaneko
RORyota Otoshi
Ryota Otoshi
ASAkimasa Sekine
Akimasa Sekine
TBTomohisa Baba
Tomohisa Baba
CYChieri Yamada
Chieri Yamada
TOTakashi Ogura
Takashi Ogura

15 April 2021 in Internal Medicine
Verified
Journal Article
Open access
PDF file
RORyota Otoshi
Ryota Otoshi
TBTomohisa Baba
Tomohisa Baba
RSRyota Shintani
Ryota Shintani
HKHideya Kitamura
Hideya Kitamura
YYYukie Yamaguchi
Yukie Yamaguchi
TOTakashi Ogura
Takashi Ogura
A 42-year-old man with a history of surgery for tongue cancer was referred to our hospital due to an abnormal chest shadow. High-resolution computed tomography showed lower lobe reticulation. A physical examination revealed nail dystrophy, oral leukoplakia, and reticulated hypopigmentation. Lung biopsy revealed subpleural and perilobular fibrosis, suggestive of usual interstitial pneumonia. However, multiple pathological findings, including homogenous fibrosis and cell infiltration in the centrilobular region, which were compatible with nonspecific interstitial pneumonia, and bronchiolitis were also seen. Genetic testing showed a hemizygous missense mutation in the DKC1 gene, and the patient was diagnosed with dyskeratosis congenita. Although anti-fibrotic therapy was initiated, the patient's respiratory function has continued to decrease.

3 November 2023 in Respiratory Investigation
Verified
Journal Article
Closed access
RORyota Otoshi
Ryota Otoshi
HKHideya Kitamura
Hideya Kitamura
TBTomohisa Baba
Tomohisa Baba
TMTatsuya Muraoka
Tatsuya Muraoka
ASAkimasa Sekine
Akimasa Sekine
TOTakashi Ogura
Takashi Ogura

19 May 2020 in International Archives of Allergy and Immunology
Verified
Journal Article
Closed access
PDF file
RORyota Otoshi
Ryota Otoshi
TBTomohisa Baba
Tomohisa Baba
NANaoto Aiko
Naoto Aiko
ETErina Tabata
Erina Tabata
SSShinko Sadoyama
Shinko Sadoyama
TOTakashi Ogura
Takashi Ogura
Introduction: Bronchial thermoplasty (BT) improves asthma-related quality of life and decreases the number of asthma exacerbations. However, the effectiveness of BT in the treatment of severe asthma with smoking history is unclear because previous studies have excluded patients with smoking history of more than 10 pack-years. Objective: The aim of the study was to clarify the effectiveness and safety of BT for severe asthma with smoking history. Methods: We retrospectively reviewed patients who received BT and compared its effectiveness and safety with and without smoking history. Results: Seven patients were assigned to the smoking group and 9 to the nonsmoking group. Before BT, despite Global Initiative for Asthma step 4 or 5 treatment including oral corticosteroids (OCS) or monoclonal antibody drugs, most patients in both groups had asthma-related symptoms every day (85.7 vs. 77.8%; p = 0.475) and frequent asthma exacerbations. After BT, in the smoking group, 3 patients could discontinue or reduce OCS and all 3 patients treated with monoclonal antibody drugs could discontinue them. In the smoking group, 6 patients (85.7%) experienced a reduction in the rate of symptoms, of which 3 patients (42.9%) had a disappearance of symptoms, similar to the nonsmoking group. BT was effective in 5 patients (83.3%) in the smoking group and 6 patients (75.0%) in the nonsmoking group. There were no severe complications. Conclusions: BT was found to be effective and safe for treatment of severe asthma with smoking history. Our results suggest that BT may be a therapeutic option for asthma-chronic obstructive pulmonary disease overlap.

4 May 2020 in Molecular and Clinical Oncology
Verified
Journal Article
Open access
PDF file
RORyota Otoshi
Ryota Otoshi
ASAkimasa Sekine
Akimasa Sekine
KOKoji Okudela
Koji Okudela
TKTakuma Katano
Takuma Katano
MAMasato Asaoka
Masato Asaoka
TOTakashi Ogura
Takashi Ogura
Miliary lung metastases are a rare form of metastasis of non‑small‑cell lung carcinoma. Miliary lung metastases commonly develop in lung adenocarcinoma with epidermal growth factor receptor mutation. In the present study, we present a case of miliary lung metastases from lung adenocarcinoma with ROS1 rearrangement. The patient, who had a history of surgery for stage IIIA lung adenocarcinoma, presented to our hospital with cough, dyspnea, and severe hypoxia. Chest computed tomography showed numerous tiny, randomly distributed nodules throughout both lungs. No metastases were observed in other organs. Molecular profiling of the surgical specimens was positive for ROS1 rearrangement. The results suggest that chest physicians should be aware that miliary lung metastases can develop in patients with lung adenocarcinoma with ROS1 rearrangement.